B. Riley downgraded shares of Geron (NASDAQ:GERN - Free Report) from a buy rating to a neutral rating in a research report report published on Thursday morning, MarketBeat.com reports. B. Riley currently has $2.00 price objective on the biopharmaceutical company's stock, down from their prior price objective of $3.50. B. Riley also issued estimates for Geron's Q1 2025 earnings at ($0.03) EPS, Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.03) EPS and Q4 2025 earnings at ($0.02) EPS.
Several other analysts have also commented on the stock. Needham & Company LLC lifted their price target on shares of Geron from $6.00 to $7.00 and gave the company a "buy" rating in a research report on Monday, January 13th. HC Wainwright lowered Geron from a "buy" rating to a "neutral" rating in a research note on Wednesday, February 26th. Finally, Barclays reiterated an "overweight" rating and set a $4.00 price target (down from $9.00) on shares of Geron in a report on Thursday. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $5.68.
Check Out Our Latest Research Report on Geron
Geron Price Performance
Shares of NASDAQ:GERN traded down $0.05 during midday trading on Thursday, hitting $1.71. The company had a trading volume of 26,490,778 shares, compared to its average volume of 14,960,246. Geron has a twelve month low of $1.46 and a twelve month high of $5.34. The stock has a market cap of $1.03 billion, a price-to-earnings ratio of -5.34 and a beta of 0.53. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74. The business's 50-day simple moving average is $2.93 and its 200-day simple moving average is $3.76.
Geron (NASDAQ:GERN - Get Free Report) last issued its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.04). The business had revenue of $47.54 million during the quarter, compared to the consensus estimate of $45.29 million. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. On average, research analysts predict that Geron will post -0.25 earnings per share for the current year.
Hedge Funds Weigh In On Geron
Institutional investors have recently bought and sold shares of the company. Creative Planning boosted its stake in shares of Geron by 23.8% in the third quarter. Creative Planning now owns 92,784 shares of the biopharmaceutical company's stock valued at $421,000 after purchasing an additional 17,837 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in Geron by 23.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,802 shares of the biopharmaceutical company's stock valued at $100,000 after buying an additional 4,094 shares during the period. abrdn plc acquired a new position in shares of Geron in the third quarter worth $6,752,000. US Bancorp DE increased its position in shares of Geron by 68.4% during the third quarter. US Bancorp DE now owns 18,296 shares of the biopharmaceutical company's stock worth $83,000 after acquiring an additional 7,429 shares during the period. Finally, Rovin Capital UT ADV acquired a new stake in shares of Geron in the third quarter valued at $62,000. 73.71% of the stock is owned by institutional investors and hedge funds.
About Geron
(
Get Free Report)
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
Further Reading
Before you consider Geron, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Geron wasn't on the list.
While Geron currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
